Company Overview of MedImmune, LLC
MedImmune, LLC, a biologics research and development company, researches, develops, and explores medicines for unmet medical needs across therapeutic areas, including respiratory, inflammation, and autoimmunity; cardiovascular and metabolic disease; oncology; neuroscience; and infection and vaccines worldwide. It offers Synagis (palivizumab), a monoclonal antibody to prevent serious lower respiratory tract disease; FluMist Quadrivalent (Influenza Vaccine Live, Intranasal), a quadrivalent influenza vaccine; and Trivalent FluMist (T/LAIV), a live attenuated influenza vaccine. The company was incorporated in 1987 and is based in Gaithersburg, Maryland with locations in Mountain View, Santa Clar...
One MedImmune Way
Gaithersburg, MD 20878
Founded in 1987
Key Executives for MedImmune, LLC
Vice President of Finance
Senior Vice President of Biopharmaceutical Development
Compensation as of Fiscal Year 2014.
MedImmune, LLC Key Developments
MedImmune to Collaborate with US National Cancer Institute
Jan 26 15
MedImmune has entered into a research collaboration with the US National Cancer Institute (NCI) that focuses on cancer immunotherapy and tumour-targeted therapies for cancer. The initial four pre-clinical research projects will involve two projects that will assess combinations of immunotherapy compounds in new, mouse models, which represent human tumours better. Specifically, one project will evaluate combination activity of four agents - MEDI4736 (PD-L1), MEDI0680 (PD-1), tremelimumab (CTLA-4), and MEDI6469 (mOX40) - in genetically engineered mouse models. Meanwhile, other projects will assess cancer vaccine combinations with three compounds - MEDI4736, tremelimumab, and MEDI6469 (mOX40) - in pre-clinical models. The other two projects will assess antibodies that particularly attack tumour cells to evaluate molecular imaging of antibody drug conjugates and evaluate the therapeutic efficacy of cancer stem cells.
Tetragenetics Collaborates with MedImmune on Multi-Target Ion Channel Drug Discovery Program
Jan 7 15
Tetragenetics Inc. announced that it will collaborate with MedImmune on antibody drug discovery research. Specifically, Tetragenetics will use its proprietary ion channel production technology, SionX, to produce up to five ion channel antigens for MedImmune’s antibody drug discovery programs. MedImmune will be provided with target ion channel antigens on a non-exclusive basis. Tetragenetics will receive up-front license fees, research funding, and milestone payments associated with pre-clinical and clinical development as well as potential product sales.
MedImmune, LLC Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015
Dec 24 14
MedImmune, LLC Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.
Similar Private Companies By Industry
Recent Private Companies Transactions